SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gabriel SE, Crowson CS. Risk factors for cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2012; 24: 1716.
  • 2
    Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007; 34: 93742.
  • 3
    Innala L, Moller B, Ljung L, Magnusson S, Smedby T, Sodergren A, et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five-year prospective study. Arthritis Res Ther 2011; 13: R131.
  • 4
    Davis JM III, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 56: 82030.
  • 5
    Boyer JF, Bongard V, Cantagrel A, Jamard B, Gottenberg JE, Mariette X, et al. Link between traditional cardiovascular risk factors and inflammation in early arthritis patients: results from a French multicenter cohort. Arthritis Care Res (Hoboken) 2012; 64: 87280.
  • 6
    Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 2010; 8: 30126.
  • 7
    Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 32531.
  • 8
    French Society of Rheumatology. 2012. URL: http://www.rhumatismes.net/fichiers/Brochure_SFR_V7.pdf.
  • 9
    Soubrier M, Zerkak D, Dougados M. Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem. J Rheumatol 2006; 33: 17669.
  • 10
    Toms TE, Panoulas VF, Douglas KM, Griffiths H, Sattar N, Smith JP, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 2010; 69: 6838.
  • 11
    Keeling SO, Teo M, Fung D. Lack of cardiovascular risk assessment in inflammatory arthritis and systemic lupus erythematosus patients at a tertiary care center. Clin Rheumatol 2011; 30: 13117.
  • 12
    Fechtenbaum J, Gossec L, Nataf H, Boumier P, Breuillard P, Gaud Listrat V, et al, and the Medical Network RHEVER. Professional practice assessment in ambulatory private rheumatology: a pilot evaluation of the medical file content for rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 3436.
  • 13
    D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 74353.
  • 14
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 15
    Agence Francaise de Securité Sanitaire des Produits de Sante. AFSSAPS guideline for the treatment of dyslipidemia. Rev Prat 2005; 55: 178893. In French.
  • 16
    Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48: 548.
  • 17
    Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care–based inception cohort. Arthritis Rheum 2005; 52: 22939.
  • 18
    Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 705.
  • 19
    American Diabetes Association. Position statements: screening for type 2 diabetes. Diabetes Care 2004; 27: s114.
  • 20
    National Institute for Health and Clinical Excellence (NICE). Clinical guideline 67. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: National Institute for Health and Clinical Excellence; 2010.
  • 21
    Schofield P, Chen R, Crichton N. Methods for assessing cardiovascular disease risk in a UK black population. Heart 2012; 98: 13737.
  • 22
    Grover SA, Lowensteyn I. The challenges and benefits of cardiovascular risk assessment in clinical practice. Can J Cardiol 2011; 27: 4817.
  • 23
    Missault L, Witters N, Imschoot J. High cardiovascular risk and poor adherence to guidelines in 11,069 patients of middle age and older in primary care centres. Eur J Cardiovasc Prev Rehabil 2010; 17: 5938.
  • 24
    Crowson CS, Gabriel SE. Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. Ann Rheum Dis 2011; 70: 71921.
  • 25
    Bell C, Rowe IF. The recognition and assessment of cardiovascular risk in people with rheumatoid arthritis in primary care: a questionnaire-based study of general practitioners. Musculoskeletal Care 2011; 9: 6974.